Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPECOVA: HIPEC with Paclitaxel in Ovarian Cancer
NCT02681432Phase 3Unknown
- Start
- Jan 2012
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paclitaxel in epithelial ovarian cancer (EOC). Primary endpoint: Overall Survival at 36 months. Status: unknown.
02
Drugs
paclitaxel
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NCT02681432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02681432.